In animal models of NSCLC, including patient-derived xenograft (PDX) tumor xenografts, W2014-S inhibited cancer growth, demonstrating proof of concept in preclinical studies of STAT3 driven NSCLC tumors [72]. This evidence concerns the gene STAT3 and neoplasm.